46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August to 1 September 2020 Scientific Programme Saturday, 29 August 2020 General 12:30 - 13:15 Auditorium 1 GS1, Opening Ceremony Welcome and introduction 12:30 - 12:35 Nicolaus Kröger (Germany) Welcome and introduction to the conference 12:35 - 12:40 Rafael Duarte (Spain) Welcome from the Nurses Group 12:40 - 12:44 John Murray (United Kingdom) EBMT Patient Advocacy Committee: Welcome note 12:44 - 12:48 Bregje Verhoeven (Netherlands) Introduction of the Keynote speaker 12:48 - 12:50 Rafael Duarte (Spain) Keynote Lecture: How the treatment is evolving in transplant-eligible 12:50 - 13:15 newly diagnosed Multiple Myeloma? María-Victoria Mateos (Spain) Industrial Theatre 12:30 - 18:30 Industry Theatre IT1, TLS in the context of new treatments in hematology - Sanofi Genzyme Industry Theatre Session Industrial Theatre 12:30 - 18:30 Industry Theatre IT3, Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite Industry Theatre Session Industrial Theatre 12:30 - 18:30 Industry Theatre IT4, KYMRIAH in the Real World - Novartis Industry Theatre Session Page 1 / 353 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August to 1 September 2020 Scientific Programme Industrial Theatre 12:30 - 18:30 Industry Theatre IT5, How I manage CMV in HSCT patients - MSD Industry Theatre Session Industrial Theatre 12:30 - 18:30 Industry Theatre IT6, Gene therapy: From clinical trials to clinical practice - Bluebirdbio Industry Theatre Session Chairs: Franco Locatelli (Italy) Industrial Theatre 12:30 - 18:30 Industry Theatre IT2, Clinical Data on Treosulfan-based Conditioning Treatment (Trecondi®) in Paediatric Patients - Medac Industry Theatre Session e-Posters 12:30 - 18:30 ePoster Area Lymphoma LONG TERM SURVIVAL AFTER 2 YEARS EVENT FREE SURVIVAL IN RELAPSED DLBCL AFTER AUTOLOGOUS TRANSPLANTATION IN THE TWO RANDOMIZED TRIALS LY.12 AND CORAL EXPLORATORY ANALYSIS OF BRENTUXIMAB VEDOTIN PLUS CHP (A+CHP) AS FRONTLINE TREATMENT FOR PATIENTS WITH CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS (ECHELON-2): IMPACT OF CONSOLIDATIVE STEM CELL TRANSPLANT BRENTUXIMAB VEDOTIN FOR RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH HODGKIN LYMPHOMA: A STUDY OF THE LWP-EBMT ALLOGENEIC STEM CELL TRANSPLANTATION AS A CURATIVE OPTION IN RELAPSE/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: SPANISH MULTICENTER GETH/GELTAMO STUDY ADAM17 INHIBITOR INCB7839 WITH RITUXIMAB AS CONSOLIDATION AFTER AUTOLOGOUS HCT FOR DIFFUSE LARGE B CELL LYMPHOMA: A NOVEL RELAPSE PREVENTION STRATEGY COMPARISON OF REDUCED-INTENSITY CONDITIONING (RIC) REGIMENS FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLO-HCT) FOR DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A CIBMTR ANALYSIS HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH NON-HODGKIN LYMPHOMA: THE SPANISH EXPERIENCE EFFICACY AND SAFETY OF DONOR LYMPHOCYTE INFUSIONS FOR PATIENTS AFFECTED BY ADVANCED LYMPHOID MALIGNANCIES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE STUDY Page 2 / 353 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August to 1 September 2020 Scientific Programme BRENTUXIMAB-VEDOTIN IN COMBINATION WITH BENDAMUSTINE AS SALVAGE THERAPY PRIOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HODGKIN LYMPHOMA: REAL-WORLD DATA FROM A TWO CENTERS STUDY NON-MYELOABLATIVE CONDITIONING REGIMEN BEFORE T-CELL REPLETE HAPLOIDENTICAL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ADVANCED LYMPHOMA IMPACT OF KIR LIGAND MISMATCH AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA: A RETROSPECTIVE STUDY IN 383 PATIENTS FROM THE SFGM-TC THE IMPACT AND CHALLENGES OF PERFORMING BEAM CONDITIONED AUTOLOGOUS TRANSPLANTS IN 'OLDER' PATIENTS WITH LYMPHOMA ACCESSIBILITY AND IMPACT ON LONG-TERM OVERALL SURVIVAL OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMAS: A SINGLE INSTITUTION INTENTION-TO-TREAT ANALYSIS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN TRANSFORMED FOLLICULAR LYMPHOMA (FL): RESULTS FROM A RETROSPECTIVE MULTICENTER STUDY FROM GELTH/GELTAMO GROUP ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR FOLLICULAR LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANTATION SIGNIFICANT ROLE OF UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA HIGH DOSE CHEMOTHERAPY TEAM FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN LYMPHOMA: RESULTS OF A PROSPECTIVE STUDY AUTOLOGOUS STEM CELL TRANSPLANTATION IN HIV+ AND HIV- LYMPHOMA PATIENTS: A PROPENSITY SCORE MATCHED ANALYSIS AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR DOUBLE HIT LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS ALLOGENEIC STEM CELL TRANSPLANTATION CAN BE SUCCESSFULLY DELIVERED FOLLOWING BTKI THERAPY FAILURE FOLLOWING R-BAC RE-INDUCTION CHEMOTHERAPY IN PATIENTS WITH MANTLE CELL LYMPHOMA CLINICAL OUTCOMES OF EBV+ PTLD PATIENTS FOLLOWING HCT WHO FAIL RITUXIMAB: A RETROSPECTIVE CHART REVIEW STUDY FROM FRANCE THE IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (ALLOHCT) ON THE OUTCOME OF POOR-RISK NON-HODGKIN LYMPHOMA (NHL): UPDATE OF A RETROSPECTIVE INTENT-TO-TRANSPLANT (ITT) ANALYSIS REDUCING THE COST OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN LYMPHOMAS AT LIMITED-RESOURCE CENTERS IN DEVELOPING COUNTRIES COMPARISON OF MITOXANTRONE - MELPHALAN AND BEAM CONDITIONING REGIMENS IN LYMPHOMA PATIENTS NIVOLUMAB RE-CHALLENGE IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: WHERE IS THE PLACE FOR ALLOHSCT? OUTCOME OF TRANSPLANT ELIGIBLE MANTLE CELL LYMPHOMA PATIENTS WITH FIRST-LINE REGIMENS IN A REAL-WORLD SETTING: A PORTUGUESE MULTICENTER RETROSPECTIVE ANALYSIS Page 3 / 353 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August to 1 September 2020 Scientific Programme EVALUATION OF FRACTIONATED ICE AS AN ALTERNATIVE OUTPATIENT OPTION FOR RELAPSED/REFRACTORY LYMPHOMAS EFFICACY OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA RISK FACTORS FOR INTENSIVE CARE UNIT ADMISSION IN PATIENTS WITH NON-HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER NIVOLUMAB TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL B-CELL LYMPHOMA DIFFERENT OUTCOMES WITH DIFFERENT DONORS IN ALLOGENEIC STEM CELL TRANSPLANTATIONS IN MALIGNANT LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE THE IRISH EXPERIENCE OF THIOTEPA, CARMUSTINE AND ETOPOSIDE CONDITIONING PRIOR TO ASCT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMAS TARGETED AND IMMUNOCHEMOTHERAPY IN RELAPSED OR REFRACTORY B-CELL NON- HODGKIN LYMPHOMA ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION AS TREATMENT OPTION FOR RARE TRANSDIFFERENTIATION OF LYMPHOID NEOPLASMS INTO HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS TO ACHIEVE LONG-TERM SURVIVAL OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR PATIENTS WITH PERIPHERAL T CELL LYMPHOMAS: A RETROSPECTIVE ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG) TREATMENT OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA AFTER HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. A STUDY OF THE POLISH LYMPHOMA RESEARCH GROUP PLACE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH T-CELL LYMPHOMAS: PAVLOV UNIVERSITY EXPERIENCE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIFFUSE LARGE B-CELL LYMPHOMA: TOXICITY AND SURVIVAL STUDY AUTOIMMUNE COMPLICATIONS IN CHILDREN WITH HODGKIN DISEASE (HD) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT) AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIV-RELATED LYMPHOMA ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A RETROSPECTIVE SINGLE-CENTER ANALYSIS OF 23 PATIENTS NIVOLUMAB BASED RESPONSE ADAPTED TREATMENT IN PRIMARY REFRACTORY HODGKIN LYMPHOMA (HL) PATIENTS AUTOLOGOUS STEM CELL TRANSPLANT IN A SEROPOSITIVE A PATIENT WITH PLASMABLASTIC LYMPHOMA (PBL) COMPAIRING THE EFFICACY AND TOXICITY BETWEEN TWO CONDITIONING REGIMEN IN LYMPHOMA PATIENTS IN WEST OF IRAN (BENDAMUSTIN) OR (CCNU) WITH (ETOPOSIDE, CITARABINE, MELPHALANE) Page 4 / 353 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August to 1 September 2020 Scientific Programme e-Posters 12:30 - 18:30 ePoster Area Acute leukaemia ALLOGENEIC TRANSPLANTATION IN PATIENTS WITH HIV-INFECTION: AN UPDATED PAIR- MATCHED COHORT STUDY BY THE EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION COMPARABLE OUTCOMES OF AML PATIENTS RECEIVING HAPLO-HCT WITH THIOTEPA/BUSULFAN/FLUDARABINE CONDITIONING AND POST-TRANSPLANT CYCLOPHOSPHAMIDE VERSUS A MATCHED UNRELATED DONOR WITH FLUDARABINE/BUSULFAN CONDITIONING, REGARDLESS OF DISEASE STATUS TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF RELAPSED ACUTE MYELOID LEUKEMIA AFTER ALLOGENEIC HEMATOPOEITIC CELL TRANSPLANT: IMPROVED SURVIVAL FOR YOUNG PATIENTS IN RECENT YEARS ANTI-CD3/CD33 BISPECIFIC ANTIBODIES EFFICIENTLY REDIRECT DONOR T CELLS AGAINST HLA LOSS LEUKEMIA RELAPSES POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) EMERGES AS A KEY DRIVER OF HLA CLASS II NEGATIVE POST-TRANSPLANTATION RELAPSE ALLOGENEIC HCT FOR ADULTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA HARBORING <i>IKZF1</i> GENE MUTATIONS: A STUDY BY THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANT IN CHILDREN AND ADULTS WITH RELAPSED/REFRACTORY